These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 14989386)

  • 21. Omalizumab for severe asthma?
    Drug Ther Bull; 2006 Nov; 44(11):86-8. PubMed ID: 17089921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omalizumab: overview of pharmacology and efficacy in asthma.
    Ledford DK
    Expert Opin Biol Ther; 2009 Jul; 9(7):933-43. PubMed ID: 19527111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omalizumab: a second look in severe persistent asthma: new adverse effects.
    Prescrire Int; 2011 Apr; 20(115):90-2. PubMed ID: 21648207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omalizumab administration in Churg-Strauss syndrome.
    Giavina-Bianchi P; Kalil J
    Eur J Intern Med; 2009 Oct; 20(6):e139. PubMed ID: 19782907
    [No Abstract]   [Full Text] [Related]  

  • 25. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of severe asthma with anti-immunoglobulin E (Omalizumab). A new possibility in pulmonary medicine].
    Nolte H; Harving H; Backer V
    Ugeskr Laeger; 2007 Dec; 169(50):4366-7. PubMed ID: 18211797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New drugs; omalizumab].
    Cohen AF; Dubois EA; van Bronswijk H
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2871-2. PubMed ID: 17319219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis.
    Cox L; Platts-Mills TA; Finegold I; Schwartz LB; Simons FE; Wallace DV; ;
    J Allergy Clin Immunol; 2007 Dec; 120(6):1373-7. PubMed ID: 17996286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Xolair in asthma therapy: an overview.
    Di Domenico M; Bisogno A; Polverino M; De Rosa C; Ricci V; Capasso A
    Inflamm Allergy Drug Targets; 2011 Feb; 10(1):2-12. PubMed ID: 21184647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunoglobulin E: role in asthma and allergic disease: lessons from the clinic.
    Owen CE
    Pharmacol Ther; 2007 Jan; 113(1):121-33. PubMed ID: 17000005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omalizumab: a steroid-sparing option for improving pediatric asthma management?
    Briars LA; Diaz A
    J Pediatr Health Care; 2005; 19(6):386-91; quiz 392-4. PubMed ID: 16286226
    [No Abstract]   [Full Text] [Related]  

  • 32. Reduction of the total immunoglobulin E level by omalizumab in children and adolescents.
    Steiss JO; Rudloff S; Lindemann H; Zimmer KP
    J Asthma; 2010 Sep; 47(7):832-3. PubMed ID: 20653498
    [No Abstract]   [Full Text] [Related]  

  • 33. Omalizumab (Xolair) in patients with steroid-resistant asthma: lessons to be learnt.
    Thompson PJ; Misso NL; Woods J
    Respirology; 2007 Nov; 12 Suppl 3():S29-34; discussion S45-7. PubMed ID: 17956517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement in quality of life with omalizumab in patients with severe allergic asthma.
    Chipps B; Buhl R; Beeh KM; Fox H; Thomas K; Reisner C
    Curr Med Res Opin; 2006 Nov; 22(11):2201-8. PubMed ID: 17076981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
    Ohta K; Miyamoto T; Amagasaki T; Yamamoto M;
    Respirology; 2009 Nov; 14(8):1156-65. PubMed ID: 19909462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [On asthma and allergic reactions. Omalizumab: from IgE to anti-IgE].
    Ladetzki-Baehs K; Dirsch VM; Vollmar AM
    Pharm Unserer Zeit; 2004; 33(2):116-22. PubMed ID: 15083621
    [No Abstract]   [Full Text] [Related]  

  • 37. Lichen planus associated with omalizumab administration in an adult with allergic asthma.
    Seeborg FO; Rihal PS; Czelusta A; Sanchez R; Hanson IC
    Ann Allergy Asthma Immunol; 2009 Apr; 102(4):349-51. PubMed ID: 19445051
    [No Abstract]   [Full Text] [Related]  

  • 38. Symptom control and improved functioning: the effect of omalizumab on asthma-related quality of life (ARQL).
    Luskin AT; Kosinski M; Bresnahan BW; Ashby M; Wong DA
    J Asthma; 2005 Dec; 42(10):823-7. PubMed ID: 16393718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma.
    Humbert M; Berger W; Rapatz G; Turk F
    Allergy; 2008 May; 63(5):592-6. PubMed ID: 18355388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-IgE therapy with omalizumab in asthma and allergic rhinitis.
    Dodig S; Richter D; Cepelak I; Benko B
    Acta Pharm; 2005 Jun; 55(2):123-38. PubMed ID: 16179127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.